Select Page

Biotech is extending last week’s breakout as the new week begins.  There is room to run as all three of the Biotech Indexes we follow are still well below overbought readings despite the huge move off the March lows.  The consolidation process through May and early June has set the sector up well for more upside.  

We are long BIB and XBI in some managed accounts.